GlassScriptPhysician profile
Edward C Juarez
NPI 1285625400
$6,779.09
in general payments reported to CMS, 2019-2025
19 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $30.03 · 2021: $1,102 · 2022: $1,381 · 2023: $790 · 2024: $1,619 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,924.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $861.03 | 2021-2024 | Xeomin |
| Globus Medical, INC. | $746.18 | 2025 | Senza |
| Abbvie INC. | $719.94 | 2023-2025 | |
| Abbott Laboratories | $705.94 | 2019-2024 | Freestyle Libre 3 |
| Nevro Corp. | $460.03 | 2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.26 | 2019-2023 | Jardiance |
| Medtronic, INC. | $382.67 | 2021-2024 | Symplicity G3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.02 | 2023-2025 | Caplyta |
| Allergan, INC. | $319.48 | 2022 | |
| Novo Nordisk INC | $315.16 | 2022-2025 | Ozempic |
| Boston Scientific Corporation | $291.30 | 2023-2025 | Wavewriter Alpha Prime 16, General - Therapies |
| Galderma Laboratories, L.P. | $245.98 | 2021 | |
| Corcept Therapeutics | $225.92 | 2021-2022 | |
| Lilly USA, LLC | $222.68 | 2022-2023 | Jardiance |
| Abiomed | $184.69 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $112.92 | 2019 | |
| Inspire Medical Systems, INC. | $101.08 | 2023 | Inspire |
| Neurocrine Biosciences, INC. | $99.02 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Juarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.